Blog
RSS FeedPosted by Michael Wonder on 11 Jun 2026
Italfarmaco announces Health Canada acceptance and priority review of new drug submission for givinostat as a Duchenne muscular dystrophy treatment
10 June 2026 - New drug submission is based on Italfarmaco’s Phase 3 EPIDYS trial data demonstrating meaningful treatment benefits ...
Posted by Michael Wonder on 08 Jul 2026
FDA approves new treatment to reduce proteinuria in adults with primary immunoglobulin A nephropathy
7 July 2026 - The US FDA has approved Trutakna (atacicept-vymj) to reduce proteinuria in adults with primary immunoglobulin A nephropathy ...
Posted by Michael Wonder on 08 Jul 2026
US FDA grants priority review to Agios’ sNDA for mitapivat in sickle cell disease
7 July 2026 - Agios Pharmaceuticals today announced that the US FDA has accepted its supplemental new drug application for mitapivat, ...
Posted by Michael Wonder on 08 Jul 2026
Patients in limbo as price disputes swamp PBS medicine approvals
8 July 2026 - The body that’s supposed to approve new drugs for listing on the PBS is instead forced to ...
Posted by Michael Wonder on 08 Jul 2026
PBS dispute could leave MS patients with huge bills for crucial drugs Ocrevus and Kesimpta
7 July 2026 - A dispute over how Australia prices medicines has sparked fears 10,000 people with multiple sclerosis will ...
Posted by Michael Wonder on 08 Jul 2026
PharmaEssentia announces Health Canada approval of Besremi (ropeginterferon alfa-2b) for polycythemia vera
7 July 2026 - PharmaEssentia today announced that its wholly owned subsidiary, FORUS Therapeutics, has received a Notice of Compliance ...
Posted by Michael Wonder on 08 Jul 2026
EMA expedites assessment of Revolution Medicines’ daraxonrasib under phased review process
7 July 2026 - Revolution Medicines today announced that EMA's CHMP has started a phased review of data on daraxonrasib, the ...
Posted by Michael Wonder on 07 Jul 2026
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
25 June 2026 - Eli Lilly today announced additional details regarding the Medicare GLP-1 Bridge program taking effect 1 July 2026. ...
Posted by Michael Wonder on 06 Jul 2026
New Zealand Pharmaceutical Schedule - 1 July 2026
1 July 2026 - The July 2026 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 06 Jul 2026
More people to access cholesterol lowering medicine
30 June 2026 - PHARMAC will widen access to rosuvastatin, a medicine used to treat high cholesterol and reduce the ...
Posted by Michael Wonder on 06 Jul 2026
PHARMAC funds another ADHD medicine to improve supply
24 June 2026 - PHARMAC will fund another brand of methylphenidate to help improve supply and provide more treatment options ...
Posted by Michael Wonder on 06 Jul 2026
New treatment option recommended for recurrent or metastatic cervical cancer
24 June 2026 - A new treatment option is now available on the NHS for cervical cancer that has come back ...
Posted by Michael Wonder on 06 Jul 2026
First disease-modifying therapy to delay the onset of type 1 diabetes recommended for NHS use
23 June 2026 - A first of its kind therapy that can delay the onset of type 1 diabetes for up ...
Posted by Michael Wonder on 06 Jul 2026
Ascelia Pharma provides update on the Orviglance NDA
3 July 2026 - Ascelia Pharma today announced that it has received a complete response letter from the US FDA regarding ...
Posted by Michael Wonder on 03 Jul 2026
Wegovy, RSV vaccines among drugs on slow track in New Zealand
2 July 2026 - Small countries in a big world can choose to be nimble or they can choose to ...
Posted by Michael Wonder on 03 Jul 2026
Selective PPARα modulator “K-808” (pemafibrate) granted breakthrough therapy designation by the US FDA as a treatment for primary biliary cholangitis
30 June 2026 - Kowa today announced that on 11 June 2026, it received breakthrough therapy designation from the US FDA ...